Navigation Links
Morphotek(R), Inc. Announces Initiation of MORAb-009 Phase II Study in First- Line Treatment of Mesothelioma
Date:3/2/2009

EXTON, Pa., March 2 /PRNewswire/ -- Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, today announced that it has commenced a multi-centered Phase II study of its MORAb-009 monoclonal antibody in mesothelioma. The study will evaluate MORAb-009, plus the chemotherapy drugs pemetrexed and cisplatinum, as a first-line treatment for patients with mesothelioma.

The primary objective of the study is to assess the efficacy of MORAb-009 as combination therapy with the current standard of care as determined by progression-free survival in patients with locally advanced malignant pleural mesothelioma. Secondary objectives include safety and anti-tumor activity of MORAb-009 as determined by objective response rate. The patient population includes individuals with locally advanced malignant pleural mesothelioma who have not received any prior treatment for their disease. Morphotek expects to enroll up to 86 patients in this clinical study, which is being conducted at clinical centers globally.

"We are excited to have initiated this Phase II study of MORAb-009 in mesothelioma in cooperation with leading physician-scientists," stated Martin D. Phillips, M.D., Chief Medical Officer at Morphotek. "Mesothelioma has a generally poor prognosis, so we hope that MORAb-009 will one day provide a benefit and hope to mesothelioma cancer patients."

MORAb-009 is a monoclonal antibody that blocks the function of mesothelin, a cell surface protein on mesothelioma, pancreatic and a subset of other types of tumor cells that can allow these cells to attach, metastasize and grow. Mesothelin has been demonstrated by several independent studies to be expressed on virtually all mesothelioma tumors. Preclinical data support the theory that MORAb-009 achieves its pharmacological effect by two mechanisms: first, by blocking mesothelin's ability to interact with its target and second, by stimulating the
'/>"/>

SOURCE Morphotek, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014 Rogne Bioscience, ... Francisco Bay Area , has acquired a licence ... Oxford,s commercialisation company. The potent anti-inflammatory activity of the ... at the University of Oxford,s Sir William Dunn ... which has raised over $1.5 million in seed financing, ...
(Date:7/31/2014)... ALBANY, New York , July 31, 2014 /PRNewswire/ ... published by Transparency Market Research "Electrodes for Medical Devices ... Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, ... Share, Growth, Trends and Forecast, 2013 - 2019," the ... USD 633.6 million in 2012 and is estimated to ...
(Date:7/31/2014)... -- Senomyx , Inc. (NASDAQ: ... science technologies to discover, develop, and commercialize novel ... supply industries, today reported financial results for the ... quarter with $33.6 million in cash and highly ... quarter Senomyx achieved another important milestone with the ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Held at ... patients with an overview of the disease and its ... drug side effects, as well as updates on the ... to Dr. Sandy Srinivas for organizing this educational opportunity,” ... kidney cancer. “Sandy and her colleagues have put together ...
Breaking Biology Technology:Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 3Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 2Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 3Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 4Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 5Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 14SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 15SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 16
... Cord Blood America, Inc. (OTC Bulletin Board: CBAI), ... http://www.cordblood-america.com ) focused on bringing the life saving ... said today that it believes the executive order signed ... of stem cell research is a significant move forward ...
... Cynvec LLC, a privately held biotechnology company focused on ... of the sindbis viral vector, today announced that Frank ... the Cowen and Company 29th Annual Health Care Conference ... p.m. ET. About Cynvec LLC , ...
... March 9 Merrimack Pharmaceuticals, Inc., a privately held ... novel treatments for cancer and autoimmune disease, today announced ... Vice President and Chief Scientific Officer and Edward (Tad) ... "Ulrik and Tad have both played critical roles ...
Cached Biology Technology:Cord Blood America Sees Significant Positives in President Obama's Lifting of Stem Cell Funding Restrictions 2Merrimack Pharmaceuticals Promotes Ulrik B. Nielsen, Ph.D. to Chief Scientific Officer and Edward J. Stewart to Senior Vice President of Business Development 2
(Date:8/1/2014)... two Simon Fraser University research associates, cite new ... collaborate closely on minimizing damage to the natural ... Maureen Ryan, David H. Smith Conservation Research Fellows ... international co-authors of the newly published research in ... , Shale gas development is the extraction of ...
(Date:7/31/2014)... prestin was found to be a key gene responsible for ... the hair cells of the inner ear that contracts and ... an antique phonograph horn, amplify sound waves to make hearing ... in the advanced online edition of Molecular Biology and ... has also independently evolved to play a critical role in ...
(Date:7/31/2014)... the National Science Foundation (NSF), counters a widely-held ... warming, indicating instead that certain Arctic lakes store ... atmosphere. , The study, published this week ... thermokarst lakes, which occur as permafrost thaws and ... water, converting what was previously frozen land into ...
Breaking Biology News(10 mins):Scientists warn time to stop drilling in the dark 2Scientists warn time to stop drilling in the dark 3Certain Arctic lakes store more greenhouse gases than they release 2
... HOBOKEN, N.J. (June 23, 2010) An estimated 60 ... commonly known as hay fever, according to the American Academy ... allergic inflammation of the nasal airways that causes itching, swelling, ... the June 14, 2010 issue of Phytotherapy Research ...
... scientists from the University of Nevada, Reno, DRI, Arizona ... from a two-week expedition to Guatemala,s tropical high-mountain Lake ... the algae blooms that have assailed the ecosystem and ... lake,s water is contaminated with watershed runoff and waste ...
... In what is believed to be the largest review of the ... more likely to clump faster than others, scientists at Johns Hopkins ... they say likely control that bodily function. "Our results give ... from these genes, to develop tests that could help us identify ...
Cached Biology News:Study demonstrates pine bark naturally reduces hay fever symptoms 2Study demonstrates pine bark naturally reduces hay fever symptoms 3American team of scientists help protect Guatemala's Lake Atitlan 2American team of scientists help protect Guatemala's Lake Atitlan 3Genetic septet in control of blood platelet clotting 2Genetic septet in control of blood platelet clotting 3
...
... is collected off the clot from fasted Cynomolgus monkeys ... Available Anticoagulants: N-02: Citrate ... N-08: Potassium Oxalate N-10: EDTA (Na) ... N-07: CPD N-09: K3EDTA N-11: ...
3'-O-Methylguanosine 5'-Triphosphate, Sodium, 1 umol. Category: Nucleotides & Enzymes & Biochemicals, Nucleotides, Additional Nucleotide Products....
Recombinant Viral CCI/Fc Chimera, CF...
Biology Products: